Global key figures
At a glance
In fiscal year 2010, Daiichi Sankyo increased its net sales from €7.56 billion to €8.55 billion. Net income rose to €619.8 million. These results were achieved by about 30,500 employees worldwide. Daiichi Sankyo is a public-listed company with more than 115,142 shareholders. About 30 per cent of our shareholders come from outside Japan.
This figure of foreign investors is only slightly below the pharmaceutical industry average. Nevertheless, almost 70 per cent of shares are held by Japanese investors. In fiscal year 2010, Daiichi Sankyo invested €1.72 billion in research and development, 20.1 per cent of its net sales.
Consolidated financial summary
The fiscal years of Daiichi Sankyo Company, Limited, and its consolidated affiliates end on 31 March. In fiscal year 2010, Daiichi Sankyo increased its net sales from €7.56 billion to €8.55 billion. In the same year, net income rose to €619.8 million.
Fiscal year (million of Euros*) | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|
Net sales | 8,551 | 7,556 | 6,684 | 6,985 | 7,377 |
Cost of sales | 2,490 | 2,207 | 1,702 | 1,862 | 2,105 |
R&D expenses | 1,718 | 1,562 | 1,465 | 1,298 | 1,355 |
R&D expenses to net sales % | 20.1 | 20.7 | 21.9 | 18.6 | 18.4 |
Operating income | 1,080.7 | 758.0 | 705.3 | 1,244.7 | 1,081.9 |
Net income (loss) | 619.8 | 332.2 | - 1,710.3 | 775.1 | 623.4 |
*The Euro amounts are based on conversions from Japanese yen, solely for convenience, at a rate of ¥113.13=€1(FY2010) and ¥126=€1 for FY’s 2006 – 2009, the approximate exchange rate on 31 March 2011.
Overseas sales to net sales
The ratio of overseas sales has steadily increased in the past years. By 2015, Daiichi Sankyo intends to generate 60 per cent or more of its turnover outside Japan.
The biggest market for Daiichi Sankyo remains Japan, followed by the United States with sales of about ¥184,4billion (in fiscal year 2010). Except for Daiichi Sankyo Inc., other affiliates contribute additionally to this figure. One of them is Luitpold Pharmaceuticals Inc., a former affiliate of a German mid-sized pharmaceutical company that Sankyo acquired in 1990.
In terms of sales figures, Europe is the third most important market for the Daiichi Sankyo Group. Here, turnover of almost €587 million was realized in 2010. The biggest markets for Daiichi Sankyo in Europe are Germany, France, Italy and Spain.
Research and development expenses
With a research and development spending of €1.72 billion in fiscal year 2010, Daiichi Sankyo has invested more than 20 per cent of its net sales into the future of the company. This amount far exceeds the industry average of 15-17 per cent. This emphasizes the importance of organic growth for the business strategy of Daiichi Sankyo.
In its research activities the company focuses on thrombotic disorders, novel oncology and cardiovascular-metabolic therapies. Daiichi Sankyo aims to invent drugs that are either “Best-in-Class” or create a new class of therapeutic solutions.
Pipeline information
Global reach
By linking into Ranbaxy's network, Daiichi Sankyo has dramatically extended its global reach and is tapping a marketing network that in addition to the traditionally big pharmaceutical markets in the United States, Europe and Japan covers many emerging countries to which Daiichi Sankyo previously had no direct access. Here, unmet medical needs of patients are much higher than in Western or Japanese societies and the markets in emerging countries are predicted to play a dominant role in the global growth of pharmaceutical companies.